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Abstract
Background: Increasing numbers of patients with elevated anti-N-methyl-D-aspartate (NMDA) receptor antibody
titers presenting exclusively with psychiatric symptoms have been reported. The aim of the present study was to
clarify the prevalence of elevated serum anti-NMDA receptor antibody titers in patients with new-onset or acute
exacerbations of psychiatric symptoms. In addition, the present study aimed to investigate the association between
elevated anti-NMDA receptor titers and psychiatric symptoms.
Methods: The present collaborative study included 59 inpatients (23 male, 36 female) presenting with new-onset
or exacerbations of schizophrenia-like symptoms at involved institutions from June 2012 to March 2014. Patient
information was collected using questionnaires. Anti-NMDA receptor antibody titers were measured using NMDAR
NR1 and NR2B co-transfected human embryonic kidney (HEK) 293 cells as an antigen (cell-based assay). Statistical
analyses were performed for each questionnaire item.
Results: The mean age of participants was 42.0 ± 13.7 years. Six cases had elevated serum anti-NMDA antibody
titers (10.2 %), four cases were first onset, and two cases with disease duration >10 years presented with third and
fifth recurrences. No statistically significant difference in vital signs or major symptoms was observed between
antibody-positive and antibody-negative groups. However, a trend toward an increased frequency of
schizophrenia-like symptoms was observed in the antibody-positive group.
Conclusion: Serum anti-NMDA receptor antibody titers may be associated with psychiatric conditions. However, an
association with specific psychiatric symptoms was not observed in the present study. Further studies are required
to validate the utility of serum anti-NMDA receptor antibody titer measurements at the time of symptom onset.
Keywords: Psychiatric symptom, Schizophrenia, Anti-N-methyl-D-aspartate receptor antibody, Human embryonic
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Background
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis
with a characteristic clinical course was proposed in 2007
by Dalmau et al. [1]. The disease classically progresses
from flu-like to schizophrenia-like symptoms, leading to
intractable convulsions, involuntary movements, and
ultimately, an unresponsive state requiring artificial respir-
ation management for central hypoventilation. However,
many severe cases will make a full recovery [1]. Approxi-
mately half of affected patients are found to have an ovar-
ian teratoma with early tumoral excision reported to be
associated with improved recovery phase. Administration
of immunomodulating drugs, including adrenal corticoste-
roids, large doses of intra-venous immunoglobulins, and
plasma exchange, represents the first-line treatment for
anti-NMDA receptor encephalitis. Immunosuppressive
drugs, including cyclophosphamide and rituximab, are rec-
ommended as second-line treatments [2].
However, there has been a recent increase in reports
of anti-NMDA receptor encephalitis in patients without
ovarian tumors, including male and pediatric cases.
We previously reported the case of an 18-year-old man
with anti-NMDA receptor antibodies who developed psy-
chiatric symptoms following type B influenza virus infec-
tion. The patient did not develop severe symptoms such
as convulsions or central hypoventilation and experienced
a full recovery following modified electroconvulsive ther-
apy for psychiatric symptoms.
Anti-NMDA receptor encephalitis is often managed by
psychiatry departments as patients typically present exclu-
sively with psychiatric symptoms, as in the present case.
The prevalence of anti-NMDA receptor antibodies has
previously been reported; however, this was a retrospective
study that predominantly used preserved specimens.
We prospectively examined cases with the develop-
ment of new-onset or exacerbations of psychiatric symp-
toms to assess the prevalence of anti-NMDA receptor
antibody positivity and assess its association with psychi-
atric symptoms in a multi-center collaborative study.
Methods
Study setting and subjects
The present study included inpatients that developed
new-onset or exacerbations of schizophrenia-like symp-
toms and were from neurology and psychiatry depart-
ments at institutions from June 2012 to March 2014.
Target cases were chosen by the study partaker of each
institution. When agreement was not provided by the
patients themselves, we explained the purpose of the
present study to a family member and obtained their
consent. We obtained written consent from patients
and/or their families (caregivers) when patients were un-
able to comprehend because of psychiatric symptoms.
Furthermore, written consent to publication of more
detailed clinical information such as age, sex, and symp-
toms was included.
The present study was conducted with the approval of
the Bioethics Committee for Clinical Research, Jichi Med-
ical University Hospital. Any collaborating institution with-
out its own ethical review board was also represented by
the Bioethics Committee for Clinical Research, as requested
in writing.
A total of 59 cases (23 male, 36 female) were enrolled.
The mean age was 42.0 ± 13.7 (SD) years. Twenty-one pa-
tients had a first episode of symptoms, 37 had recurrent
episodes (second, third, fourth, and fifth recurrences in 19,
five, three, and ten patients, respectively), and one case
was unclear.
Patient information was collected using a questionnaire
completed by participants. The initial questionnaire at the
time of the first examination included questions regarding
age, sex, blood pressure, pulse rate, body temperature, and
Japan coma scale (JCS). Further sections were as follows:
clinical diagnosis according to Diagnostic and Statistical
Manual of Mental Disorders IV text revision (DSM-IV
TR); history of preceding infection; characteristics of
onset or recurrence; number of recurrences and disease
duration; psychiatric symptoms (anxiety/depression, mania,
or schizophrenia-like symptoms); and neurological symp-
toms. Furthermore, we included items related to psychiatric
symptoms and neurological symptoms (Table 1). The JCS
is the original Japanese consciousness scale and is more
widely used than the Glasgow coma scale (GCS) in Japan.
However, the accurate comparison of scores between the
GCS and JCS is challenging as there is no item correspond-
ing to the “Verbal” score in the JCS. A consciousness score
of 0 indicates the patient is lucid, and scores of 1–3 are
equivalent to a GCS of E4, indicating spontaneous eye-
opening. Scores of 10–30 indicate eye-opening in response
to stimulation, with a score of 10 being equivalent to a
GCS score of E3 and scores of 20–30 being equivalent to
E2. Scores >100 are equivalent to E1, and a score of 300 is
equivalent to a score of M1 on the GCS.
Statistical analyses
Patients were divided into two groups on the basis of
the presence or absence of anti-NMDA receptor anti-
bodies, and answers to individual questionnaire items
were compared. Welch’s t-test was performed for com-
parison of continuous variables, including age, blood
pressure, pulse rate, and body temperature. For categor-
ical data such as sex and items assessing the presence or
absence of symptoms, Fisher’s direct exact test was used
because of the small number of antibody-positive pa-
tients. JCS at the time of the hospitalization was divided
into seven classes: 0, 1, 5, 3, 10, 30, and 100. The num-
ber of recurrences was divided into five classes: 1, 2, 3,
4, and >5. Disease duration was divided into seven
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classes: first, 1 month, 3 month, 1 year, 5 years, 10 years,
and >10 years, which were assessed using the Mann–
Whitney U test. All statistics were performed using the
software “Stat Flex ver.6”(Artech, Osaka, Japan). All tests
were two-tailed, and significance was set at P < 0.05.
NMDA receptor antibody measurements
Blood and/or cerebrospinal fluid was collected at the time
of hospitalization at each institution. Serum was extracted,
frozen, and stored until further use. All samples were
anonymized and sent to the Department of Neurology,
Jichi Medical University. A frozen serum specimen for
each patient was subsequently sent to the Department of
Neurology, Kanazawa Medical University.
All serum obtained at the first study visit was mea-
sured using the following methods.
Human embryonic kidney (HEK) 293 cells trans-
fected with plasmid DNAs encoding the NMDA
receptor subunits NR1 and NR2B with cell membrane
co-expression were used [3]. Cell culture was main-
tained in Dulbecco’s modified Eagle's medium with
10 % fetal calf serum supplemented with 10 μM MK-
801 (Wako, Tokyo, Japan) for neuroprotection. At
12 h after transfection, HEK cells were fixed in 4 %
paraformaldehyde in 0.1 M phosphate-buffered saline
(PBS, pH 7.4) for 20 min. Non-specific binding was
blocked with 10 % goat serum/PBS, and cells were in-
cubated with patient sera (1:10–400) in 0.02 % Triton
X-100 and 10 % goat serum in PBS overnight at 4 °C
and then with fluorescein isothiaocyanate (FITC)-con-
jugated anti-human IgG (DAKO, Glostrup, Denmark;
1:50) and phycoerythrin (PE)-conjugated anti-rabbit
IgG secondary antibodies (DAKO, Glostrup, Denmark;
1:50) for 1 h. SlowFade Gold anti-fade reagent (Invi-
trogen Japan, Tokyo) was then applied to the slides,
and staining was observed under a fluorescence
microscope (Axiovision, Zeiss). To confirm the
localization of NMDAR antibody-binding sites, double
staining was performed with both patient samples and
a mixture of rabbit anti-NR1 (PhosphoSolutions, CO,
USA; 1:10) and anti-NR2B (Frontier Science, Sapporo,
Japan; 1:10) antibodies. Then, primary antibodies were
visualized by FITC-anti-human IgG and R-PE-anti-
rabbit IgG and observed under a laser scanning
microscope (Zeiss LSM 710). IgG binding was con-
firmed as IgG1. No staining was observed in HEK
cells expressing homomeric NR2B subunits or trans-
fected with an empty vector. Serial dilutions were
used, and where co-localization was observed, anti-
body titers were measured (Fig. 1). Serum from sub-
sequent follow-up visits was analyzed using the same
methodology.
Immunohistochemistry
Paraffin-embedded sections of mouse brain (Genostaff Co.
Ltd. Tokyo, Japan) were stained with rabbit anti-GluN1
antibody and anti-GluN2B antibody (Frontier Institute Co.
Ltd. Hokkaido, Japan) at a 1:200 dilution or human serum
at a 1:1000 dilution that included the serum of an antibody-
positive 59-year-old male patient. Staining was detected
using biotinylated anti-rabbit or anti-human Ig secondary
antibodies (Vector Laboratories, Inc., Burlingame, CA,
USA). For histochemical evaluation, hematoxylin staining
was used to visualize the overall structure of each section.
Animal experiments
Animal experiments were conducted in a humane manner
after receiving approval from the Institutional Animal
Experiment Committee of the GENOSTAFF CO.LTD.
and in accordance with the Institutional Regulation for
Table 1 Study questionnaire
ID: Initial: Sex: Age:
Blood pressure, Pulse rate, Body temperature
Japan coma scale
(1) DSM-IV diagnosis:
(2) Precedent infectious symptoms (fever/headache/throat pain/
diarrhea)
(3) The first episode or the exacerbation
3–1) How much time had passed from the onset of symptoms
until receiving a medical examination?
3–2) How long have you been under psychiatric care in the hospital?
less than 1 month/less than 3 months/less than 1 year
less than 5 years/less than 10 years/more than 10 years
3–3) How many times did your symptoms exacerbate?
two/three/four/five/more than five
(4) Psychiatric symptom(s) (possible plural answers)
a) anxiety/depression symptom
irritation/anxiety/depressive mood/depersonalization










instability of blood pressure and pulse/sweat and drooling
abnormality
respiratory depression/disorientation/amnesia
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Animal Experiments and Fundamental Guideline for
Proper Conduct of Animal Experiment and Related Activ-
ities in Academic Research Institutions under the justifica-
tion of the Ministry of Education, Culture, Sports, Science
and Technology.
Results
Six out of 59 cases had detectable serum anti-NMDA
antibody titers (10.2 %). The clinical diagnosis at the
time of initial examination in anti-NMDA receptor
antibody patients was schizophrenia in four cases,
major depression in one case, and undetermined in
one case. Four cases were new onset, and the other
two cases had a disease duration of greater than
10 years, with third and fifth recurrences.
Clinical features of NMDA antibody-positive and
antibody-negative patients are shown in Table 2. With
regard to episode recurrence, initial and recurrent epi-
sodes were observed in 53 antibody-negative patients, and
no difference in the proportion of recurrent episodes was
observed between the antibody-negative and antibody-
positive groups by the Mann–Whitney test (P = 0.329). In
addition, no significant difference in disease duration was
observed between groups (P = 0.499).
The mean age of patients in the antibody-positive and
antibody-negative groups was 41.7 ± 16.2 and 41.9 ±
13.5 years, respectively, with no significant difference
being observed between groups (P = 0.977). There was a
higher proportion of females in the study overall, with ra-
tios of 60.4 and 66.7 % in antibody-negative and antibody-
positive groups, respectively. No significant difference in
gender was observed between groups (P = 1.000).
No significant differences in systolic blood pressure
(P = 0.648), diastolic blood pressure (P = 0.578), or body
temperature (P = 0.547) were observed between groups
at the time of the first examination; however, there was
a trend toward a higher pulse rate in the antibody-
negative group than in the antibody-positive group
(96.7/min vs. 80.3/min, P = 0.0971).
With regard to the consciousness level at the time of the
first examination, the majority of patients were either lucid
or slightly confused; however, a number of patients in the
antibody-negative group presented with somnolence or
semi-coma. No significant difference in the numerical
distribution of JCS scores was observed between groups
(P = 0.424).
No differences in the frequency of preceding infec-
tions (P = 0.581) or the proportion of patients reporting
depression/anxiety symptoms (P = 0.382), mania symp-
toms (P = 0.660), convulsions (P = 1.000), involuntary
movements (P = 1.000), blood pressure and pulse rate
fluctuations (P = 1.000), dyshydrosis (P = 1.000), or am-
nesia (P = 0.594) were observed between groups.
However, there was a trend toward a greater proportion
of antibody-positive patients reporting schizophrenia-like
symptoms (P = 0.198). Furthermore, there was a slight
trend toward reporting of blunting of feelings (P = 0.362),
delusion (P = 0.323), and obfuscation (P = 0.577) in
antibody-positive patients. No significant differences in
any other lower-rank items were observed between
groups.
Neurological symptoms such as confusion, dyskinesia,
sweating, and amnesia have been reported by psychiatrists
(not neurologists) in seronegative patients. Accordingly,
the term “psychiatric symptom cases” may not be entirely
appropriate as symptoms were very mild compared with
those of NMDA encephalitis, and neurological symptoms
are rarely reported in antibody-positive cases.
The six antibody-positive patients were followed up for a
mean duration of 5.5 ± 1.4 months. Psychiatric symptoms
resolved in three cases, and the other three cases entered a
state of amelioration. Oral medication was maintained in
all cases (Table 3). Thoracoabdominal-enhanced computed
tomographic imaging was performed in all cases for tumor
surveillance. One case of uterine myoma was identified in a
female patient. No ovarian teratomas, seminomas, or ger-
minomas were detected in any cases. Furthermore, we
measured serum tumor marker levels, which were all
Fig. 1 Immunohistochemical analyis of HEK cells co-expressing NR1 and NR2B subunits. HEK cells were incubated in patient serum (1:20 dilution) and
rabbit anti-NR1 antibody (1:100 dilution). a FITC-conjugated anti-human IgG visualized as blue fluorescence. b PE-conjugated anti-rabbit IgG visualized
as red fluorescence. c Co-localization of blue and red fluorescence indicating reaction to the same epitope (NR1 subunit). d Negative control (HEK cells
transfected with empty vector)
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59/M Major depression >10 years 3 Delusion, Anxiety, Insomnia,
Irritation, Suicidal feeling,
Excitement, Obfuscation












No tumor Not examined
56/F Schizophrenia 0 1 Catalepsy, Irritation,
Insomnia, Polyphrasia
×10 None 5 months <×2
(Negative)
No tumor Not examined






5 months ×5 (Positive) No tumor On 11 months from onset,
tonic symptom remains,
antibody dilution titer < ×2







No tumor Not examined
47/F Undetermined→
Schizophrenia
0 1 Excitement, Catatonia,
Obfuscation






















Age 41.67 ± 16.21 41.89 ± 13.54 0.9775 Welch’s t test
Sex (M/F) 2/4 21/32 1.0000 Fisher’s direct exact test
Pulse rate (/min) 80.33 ± 17.42 96.66 ± 21.35 0.0971 Welch’s t test
Systolic blood pressure (mmHg) 122.17 ± 19.71 126.42 ± 20.83 0.6483 Welch’s t test
Diastolic blood pressure (mmHg) 78.17 ± 13.53 81.76 ± 14.51 0.5782 Welch’s t test
Body temperature (°C) 36.55 ± 0.65 36.74 ± 0.46 0.5471 Welch’s t test
Japan coma scale (0/1/2/3/10/30/100) 4/2/0/0/0/0/0 19/12/5/3/1/1/1 0.4245 Mann–Whitney U test
Precedent infection 0 8 0.5812 Fisher’s direct exact test
Episode times (1/2/3/4/>5) 4/0/1/0/1 17/19/4/3/9 0.3291 Mann–Whitney U test
Treatment period (0/3 months/1 years/5 years/10 years/>10 years) 4/0/0/0/0/0/2 18/1/1/2/11/8/10 0.4987 Mann–Whitney U test
Anxiety/Depression symptoms 3 36 0.3822 Fisher’s direct exact test
Irritation 3 23 1.0000
Anxiety 2 24 0.6814
Depressive mood 1 6 1.0000
Depersonalization 0 0 *
Sleep disorder 2 25 0.6752
Will drop 1 5 1.0000
Concentration drop 1 8 1.0000
Suicidal feeling 1 8 1.0000
Mania symptoms 1 16 0.6597
Hyperthymia 1 10 1.0000
Hyperlogia 1 11 1.0000
Hyperactivity 0 4 1.0000
Flight of idea 0 2 1.0000
Schizophrenia-like symptoms 5 51 0.1978
Auditory hallucination 3 31 0.6838
Visual hallucination 0 3 1.0000
Delusion 3 40 0.3231
Obfuscation 2 8 0.5770
Excitement 3 24 1.0000
Echolalia 0 0 *
Echopraxia 0 3 1.0000
Stereotypic language 0 0 *
Stereotypic movement 0 0 *
Catalepsy 0 4 1.0000
Idle–Autosynnoia 0 4 1.0000
Flattened feeling 1 3 0.3619
Neurological symptoms 0 1 1.0000
Convulsion (Complex partial seizure) 0 1 1.0000
Orolingual dyskinesia 1 2 0.2838
Systemic dyskinesia 0 1 1.0000
Eye ball dyskinesia 0 2 1.0000
Instability of blood pressure 0 1 1.0000
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within the normal range in all cases, expect one case with a
slightly elevated neuron-specific enolase (NSE) level.
We measured serum titers of anti-NMDA antibodies in
the six antibody-positive patients at the second visit. In
four of the six cases, antibody levels became undetectable
at a twofold dilution. The other two cases remained posi-
tive at the second visit; however, titers were reduced from
the first visit in both patients. One case was a 44-year-old
man who presented with onset of delusion, auditory hallu-
cination, and anxiety. He was diagnosed with developmen-
tal disability in a hypertonic state at the time of the
follow-up survey 5 months later. The serum antibody titer
was detectable at a 20-fold dilution at the first visit and
remained detectable at a fivefold dilution at the second
visit. Serum titers became negative another 11 months
later; however, he remained symptomatic.
The other case was a 47-year-old woman who was
initially undiagnosed before receiving a diagnosis of
schizophrenia according to the DSM-IV TR. Her psy-
chiatric symptoms began with the onset of excitement
and catatonic substupor, with initial serum antibody
titers being detectable at a 20-fold dilution. The patient
demonstrated no apparent symptoms at the follow-up
survey 6 months later; however, serum antibody titers
remained detectable at a 10-fold dilution. Following this
visit, the patient discontinued her medication, leading to
recurrence of obfuscation and auditory hallucination
symptoms 8 months following the first episode. She was
hospitalized in a mental hospital for 2 months and
received medical therapy thereafter. No symptoms were
apparent 16 months after the first episode. However, we
were unable to obtain her final serum antibody titer.
For comparison, we performed immunohistochemical
analysis of paraffin-embedded mouse brain specimens.
Antibodies against the NR1 and NR2B subunits of the
NMDA receptor were used as positive controls. The
cerebral cortex, cerebellum, hippocampus, and basal
nucleus were stained by the NR1 antibody, and the
hippocampus and basal nucleus were stained particularly
strongly by the NR2B antibody. No staining was
observed using the serum of healthy controls or non-
specific IgG serum as a negative control. The cerebral
cortex, cerebellum, hippocampus, and basal nucleus
were stained by the serum of a 59-year-old man who
was anti-NMDA receptor antibody-positive at the time
of the initial examination. The staining pattern was simi-
lar to that observed with the NR1 antibody. Serum
obtained when the patient had become antibody-
negative 7 months after the first episode demonstrated
no staining, with comparable findings to those observed
with healthy control serum (Fig. 2).
Discussion
The NMDA receptor antibody was first reported by
Dalmau et al. as the antibody responsible for autoimmune
encephalitis in young women with ovarian tumors, which
follows a characteristic clinical course. It has subsequently
become clear that elevation of NMDA receptor serum
titers is associated with variable clinical courses [1, 2].
The use of anti-NMDA receptor antibody measure-
ment has recently attracted great attention in the field of
psychiatry. In addition, there are many reports of the as-
sociation between elevations of serum NMDA receptor
antibody levels and various diseases presenting with psy-
chiatric symptoms.
Rhoads et al. [4], Haussleiter et al. [5], and Masdeu et al.
[6] reported no cases of elevated serum anti-NDMA re-
ceptor antibody titers in patients with schizophrenia; how-
ever, Zandi et al. reported elevated levels of 6.5 % in
patients with early-phase psychiatric disorder [7], and
Tsutsui et al. reported a prevalence of 7.8 % in patients
with schizophrenia. Furthermore, a high prevalence of ele-
vated titers of 60 % has been reported in narcoleptic pa-
tients with psychiatric symptoms [8]. Steiner et al.
reported elevated titers in 9.9 % of patients with schizo-
phrenia and 2.8 % of patients with major depression in
2013 [9]. Hammer et al. evaluated the preserved serum of
more than 1000 patients with schizophrenia and reported
a prevalence of 8.6 % [10]. In the present study, the preva-
lence of elevated anti-NMDA receptor antibody titers was
10.2 %, and it was found to be 9.1 % in patients initially
diagnosed with schizophrenia. This prevalence is in ac-
cordance with previous reports (Table 4).
Elevated titers were observed in cases with third and
fifth recurrences greater than 10 years after the initial
diagnosis and in new-onset cases. Previous studies have
retrospectively measured antibody titers using preserved
serum and performed clinical examination of seroposi-
tive patients to assess symptoms; however, these studies
were unable to follow-up with patients and assess later
changes in antibody titers and symptoms.
We prospectively examined new inpatients, in con-
trast to previous studies, and followed-up with sero-
positive patients. Furthermore, we demonstrated the
Table 3 Result of statistical analysis (Continued)
Sweating and drooling abnormality 0 3 1.0000
Disorientation 0 0 *
Amnesia 0 7 0.5739
* statistical examination was not performed
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normalization of elevated serum anti-NMDA receptor
antibody titers with symptom improvement in five of
six seropositive cases. This result indicates the anti-
NMDA receptor antibody may influence the progres-
sion of psychiatric symptoms.
However, our findings raise two important issues
regarding this hypothesis. First, antibody titers remained
elevated in two cases despite the resolution of psychiatric
symptoms. Second, when comparing major symptoms at
the time of onset in antibody-positive patients against
antibody-negative patients, we observed no statistically
significant differences in the frequency of different symp-
toms between the two groups.
In addition, Hammer et al. reported the prevalence of ele-
vated serum anti-NMDA receptor antibody titers to be
10.8 % in healthy controls, which is higher than the value of
8.6 % observed in preserved specimens from schizophrenia
cases [10]. Steiner et al. reported the prevalence of elevated
titers to be 7.0 % in healthy control serum by supplemen-
tary examination in 2014 [11]. Further, Steiner et al. posited
that this increase in the reported prevalence was likely due
to differences in measurement method between commer-
cial kits; however, Hammer et al. utilized a HEK cell-based
assay, as described previously [10]. Interestingly, recent evi-
dence has indicated a constant prevalence of elevated titers
in the healthy general population.
A control group was not included in this study
because we initially aimed to compare symptoms of pa-
tients between the presence or absence of anti-NMDA
antibodies. However, a control group could have been
useful for the interpretation of results, using the same
method of data comparison between a control group
and past records of healthy subjects.
Maneta et al. posited that psychiatric symptoms de-
velop only when environment factors such as increased
cytokine levels in association with schizophrenia affect
the blood–brain barrier allowing anti-NMDA receptor
antibody present in the serum to enter the central ner-
vous system, thereby leading to the development of
symptoms [12].
In typical NMDA receptor encephalitis, the mechan-
ism underlying symptom onset is more apparent as the
immune system is activated by preceding infection in
the presence of autoantibodies against ovarian teratoma.
However, increasing numbers of atypical cases without
preceding infection or ovarian teratoma, as described in
the original typical cases, are being reported. Thus, the
determination of causative environmental factors in the
present antibody-positive cases that have neither tumors
nor preceding infection is particularly challenging.
Maneta et al. described a correlation between anti-
NMDA receptor antibody titers and the severity of
Fig. 2 Immunohistochemical analysis of paraffin-embedded mouse brain specimens. a The cerebral cortex, basal nuclei, and cerebellum were
widely stained by anti-GluN1 (NR1) antibody at a 200-fold dilution. b Particularly strong staining of the hippocampus and basal nuclei was
observed with the anti-GluN2B (NR2B) antibody at a 200-fold dilution. The characteristic staining pattern was not observed with healthy control
serum at a 1000-fold dilution (c) and with nonspecific IgG at a 200-fold dilution (d). e Representative images of extensive staining with anti-GluN1
from the serum of a 59-year-old male patient at onset at a 1000-fold dilution. f The characteristic stain was not observed with the use of serum
from a healthy control patient whose symptoms improved at a 1000-fold dilution
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symptoms [12]. We followed-up symptom severity
and antibody titers in antibody-positive patients. Anti-
body titers decreased in parallel with symptomatic
improvements in six antibody-positive patients in-
cluded in the present study. In the other two cases
that remained positive at the second visit, antibody
titers decreased from the first visit in both patients.
However, antibody titers in the asymptomatic female
case were higher than those in the symptomatic
male case (10-fold vs. fivefold). This finding indicates
that individual changes in antibody titers may reflect
a disease condition; however, the measurement of
antibody titers has limited utility in disease condi-
tions between multiple patients. Future studies are
required to validate the utility of determining the
absence of symptom recurrence in confirming the
antibody-negative status and clarifying the association
between antibody titer levels and symptomatic changes.
Cerebrospinal fluid (CSF) anti-NMDAR antibody titers
are thought to provide a more accurate reflection of en-
cephalitis symptoms than serum titers. Furthermore, our
results corroborate the findings of a previous study
reporting that CSF and serum antibody titers tend to
decrease with amelioration of symptoms, even if titer
Table 4 Comparison of previous reports
n M/F Diagnosis Positive Prevalence Antibody measure method
Rhoads et al. 2011 [4] 7 3/4 Schizophrenia 0 0.0 % Cell-based assay NR1
Zandi et al. 2011 [7] 46 ns Early-stage psychiatric disorder 4 6.5 % Cell-based assay NR1/NR2B
Schizophrenia 63 %
Atypical psychosis 15 %
Mood disorder 4 %
Bipolar disorder 4 %
Major depression 2 %
Paranoia 2 %
Haussleiter et al. 2012 [5] 50 17/33 Psychiatric disorder 0 0.0 % Cell-based assay NR1/NR2B, NR1/NR1
Masdeu et al. 2012 [6] 80 Schizophrenia 0 0.0 % Cell-based assay NR1
Tsutsui et al. 2012 [8] 51 ns Schizophrenia 4 7.8 % Cell-based assay NR1/NR2B
5 ns Narcolepsy with psychiatric symptom 3 60.0 %
Steiner et al. 2013 [9] 121 77/44 Schizophrenia 12 9.9 % Cell-based assay NR1/NR2B
70 26/44 Major depression 2 2.8 %
38 14/24 Borderline personality disorder 0 0.0 %
Hammer et al. 2014 [10] 1272 780/492 Healthy control 137 10.8 % Cell-based assay NR1/NR2B
1081 723/358 Schizophrenia 93 8.6 %
148 70/78 Affective disorder 24 16.2 %
Steiner et al. 2014 [11] 357 ns Healthy control 25 7.0 % Indirect immunofluorescence BIOCHIP
assay (commercial)
184 ns Schizophrenia 18 9.8 %
99 ns Major depression 5 5.1 %
42 ns Borderline personality disorder 1 2.4 %
Our report 2015 59 23/36 Total 6 10.2 % Cell-based assay NR1/NR2B
44 15/29 Schizophrenia 4 9.1 %
1 1/0 Major depression 1 100.0 %
4 1/3 Undetermined 1 25.0 %
1 1/0 Nonherpetic limbic encephalitis 0 0.0 %
1 0/1 Atypical psychosis 0 0.0 %
4 1/3 Acute transient psychosis 0 0.0 %
1 1/0 Bipolar disorder 0 0.0 %
2 1/1 Organic psychosis 0 0.0 %
1 1/0 Mental retardation 0 0.0 %
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levels do not become entirely negative [13]. In addition,
differences in reported symptoms according to antibody
subclass have previously been discussed [9, 11].
As the present study was conducted in psychiatric set-
tings, the collection of CSF was technically challenging,
and we were able to measure serum IgG antibody levels
only. Further, serum and CSF antibody titer levels may
not always change in parallel. Therefore, results may dif-
fer according to the use of either CSF or serum antibody
titer measurements.
Moreover, no patients received immunotherapy as the
patients included in the present study were diagnosed
with psychiatric disorders such as encephalitis and
admitted to a psychiatric hospital. Previous studies
have reported the immunosuppressive effect of anti-
psychotics, particularly dopamine D2 receptor antag-
onist, in animal experiments [14]. Although detailed
information regarding patient prescription contents
were unavailable, many patients were treated with
antipsychotic drugs, including dopamine D2 receptor
antagonists. Accordingly, the immunosuppression ef-
fect of such drugs may have influenced the disease
condition.
However, in light of recent studies, it is apparent that
NMDA receptor antibodies exert an effect on the onset of
psychiatric disease. In our study, we measured anti-
body titer using a HEK cell-based assay designed
“in-house”. This method required specialized tech-
niques and specific resources, i.e, our approach may
prove to be challenging to repeat elsewhere; thus, it
lacks universal reproducibility. Unified methods for
the measurement of serum anti-NMDA receptor titers,
ideally simple and easy to perform, are required for
determining cut-off thresholds and assessing the potential
utility of antibody titer measurements in the surveillance
of psychiatric illnesses.
Conclusion
Anti-NMDA receptor serum antibody was detected in
10.2 % of new-onset and recurring cases of acute psy-
chiatric symptoms in the present study. Serum antibody
titers may rise during symptom development, not only
during the initial onset but also during recurrent episodes.
Further, a change in antibody titers may predict the
clinical condition in individual patients. However, no
statistical differences in clinical symptoms or patient
background according to the presence of anti-NMDA anti-
bodies were observed in the present study. Furthermore,
the contribution of anti-NMDA encephalitis to psychiatric
symptom onset and the pathological significance of
elevated antibody titers remain unclear. Further studies
and the accumulation of case studies are required to
increase understanding of the pathological significance of
anti-NMDA receptor antibodies.
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